
Yourgene Health has secured Australian regulatory approval for its Insight DPYD assay, enabling its use in clinical diagnostic testing to …

The START Center for Cancer Research is partnering with Rome-based Istituti Fisioterapici Ospitalieri (IFO) to establish an early-phase oncology clinical …

AbbVie has expanded its Oxford research and development (R&D) facility with a new 12,000 sq ft site, strengthening its discovery …

As healthcare budgets become increasingly stretched by the demands of coping with long-term illnesses, interest is growing in the manufacturing …

Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory Day. Staged by the European …

Medtronic has received CE Mark approval for its Vitalis portfolio of five pacemakers, including a device designed for patients who …

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate why oestrogen receptor-positive (ER-positive) breast …

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings rather than academic centres, potentially …

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an experimental oral therapy targeting acute …

Sterling Pharma Solutions has completed a multi-million-pound expansion of its dedicated bioconjugation facility in Deeside, Wales, doubling manufacturing capacity and …

Femtosecond laser imaging has reduced the time needed to assess lung tumour margins from 36 minutes to less than six …

People in their forties account for almost three-quarters of those who do not attend NHS Health Checks, highlighting the challenge …

NICE has published final draft guidance recommending daratumumab with bortezomib, lenalidomide and dexamethasone (D-VRd) for previously untreated adults with multiple …

By Chloe Williams and Sarah Ellson Innovative therapies are transforming the treatment landscape for serious diseases, particularly cancer. Advances in …

The Japan Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the updated prescribing information for Daiichi Sankyo’s Enhertu (trastuzumab), a …